Search
Menu
Deposition Sciences Inc. - Difficult Coatings - LB - 8/23

Patent Application Filed for MOR103 Program

Facebook X LinkedIn Email
MorphoSys AG of Martinsried, Germany, and Melbourne Ventures Pty. Ltd., a wholly owned commercial subsidiary of the University of Melbourne in Australia, have formed a joint venture in the investigation of the therapeutic applications of MorphoSys’ MOR103 program, a HuCAL (Human Combinatorial Antibody Library) antibody against human GM-CSF (granulocyte macrophage-colony stimulating factor) being developed for the treatment of rheumatoid arthritis. MorphoSys also has been issued patent No. 4,312,403 from the Japanese Patent Office for its CysDisplay, a component of the HuCAL platform. The...Read full article

Related content from Photonics Media



    Articles


    Webinars


    Photonics Dictionary Terms
    Published: August 2009
    antibodiesMorphoSys AGPatent NewsSlices from the Breadboardtherapeutic applications

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.